(4,5-dimethyl-thiazol-2-yl)-isopropyl-amine | 2505-99-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (4,5-dimethyl-thiazol-2-yl)-isopropyl-amine
• 英文别名: 2-Isopropylamino-4,5-dimethylthiazole；4,5-dimethyl-N-(propan-2-yl)-1,3-thiazol-2-amine；4,5-dimethyl-N-propan-2-yl-1,3-thiazol-2-amine
• CAS: 2505-99-9
• 化学式: C₈H₁₄N₂S
• mdl: MFCD17257289
• 分子量: 170.279
• InChiKey: UVGCAPZBFZFQIP-UHFFFAOYSA-N

物化性质

• 熔点：
  100.5-102.0 °C
• 沸点：
  247.3±43.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-异丙基-2-硫脲 、 3-氯-2-丁酮 生成 (4,5-dimethyl-thiazol-2-yl)-isopropyl-amine
  参考文献：
  名称：

  Alkylation of aminothiazoles; IV. Alkylation of 2-amino-4,5-dimethylthiazole

  摘要：

  DOI：

  10.1007/bf01046690

文献信息

• METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT
  申请人：Errico Joseph P.

  公开号：US20110301193A1

  公开（公告）日：2011-12-08

  Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.

  本文提供具有抗增殖作用的化合物。还提供一些化合物，可以调节由二聚化臂和域间系带组成的多域蛋白的活性，例如EGFR，其中未系带的延伸构象是活性状态，而系带的构象是非活性状态，导致自抑制构型。还提供了用于识别此类化合物的方法和药效团。其他方面提供了治疗增殖性疾病、疾病或病状的方法或治疗。例如与EGFR相关的疾病。
• ANTIVIRAL COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20130274439A1

  公开（公告）日：2013-10-17

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  这项发明涉及抗病毒化合物、含有这种化合物的组合物以及包括给予这种化合物的治疗方法，还涉及用于制备这种化合物的过程和中间体。
• COMPOSITIONS OF TARGETED DRUG DEVELOPMENT
  申请人：Errico Joseph P.

  公开号：US20140163069A1

  公开（公告）日：2014-06-12

  Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.

  本文提供具有抗增殖效应的化合物。还提供了可以调节多域蛋白质活性的化合物，包括具有二聚化臂和域间系索的EGFR，其中无系索的伸展构象是活性状态，而系索的构象是非活性状态，导致自抑制构型。还提供了用于识别此类化合物的方法和药效团。其他方面提供了治疗增殖性疾病、疾病或病情的方法或治疗。例如与EGFR相关的疾病。
• METHODS OF TARGETED DRUG DEVELOPMENT
  申请人：Errico Joseph P.

  公开号：US20140194439A1

  公开（公告）日：2014-07-10

  Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR.

  本文提供了具有抗增殖作用的化合物。还提供了可以调节包括二聚化臂和域间连接的多域蛋白活性的化合物，例如EGFR，其中未连接的扩展构象是活性状态，连接的构象是非活性状态，导致自抑制构型。还提供了用于识别此类化合物的方法和药效团。其他方面提供了用于增殖性疾病、疾病或病情的方法或治疗，例如与EGFR相关的疾病。
• COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS
  申请人：Errico Joseph P.

  公开号：US20120156197A1

  公开（公告）日：2012-06-21

  Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.